The bank's research arm raised its rating on the stock to overweight from equal weight.
Get this delivered to your inbox, and more info about our products and services.
The investment bank upgraded the pharma stock to overweight from equal weight.
Carter Worth takes a look at the charts for mid-cap biotech Immunovant.
The bank initiated the clinical-stage biotechnology firm at a buy rating.
The bank pointed to recent M&A success as a catalyst for the stock.
BofA analysts are bullish on this German medtech name ahead of its full-year earnings report.
The investment bank upgraded the pharmaceutical name to buy from neutral.
